Financial Benefit Analysis Of M&A Of Qingjin Biomedical Device Enterprises

Competition among domestic small and medium-sized biomedical devices enterprises is intensifying,in order to achieve rapid expansion and seize market share of similar products.More and more enterprises,through financing mergers and acquisitions,realize the extension of enterprises.But can financing mergers and acquisitions really bring long-term economic growth to enterprises? Further research and analysis are needed.Beijing Qingda Biotechnology Co.,Ltd.,the main body of the M&A case study in this paper,is an enterprise mainly engaged in the research and development,production,marketing and service of biomedical materials,regenerative medicine and tissue engineering,stem cells and biotherapeutic products.It is committed to investment and project incubation in the field of biomedicine.Starting from the background environment of small and medium-sized biomedical devices enterprises,this paper summarizes the concept and evaluation methods of M&A performance based on the theoretical research of M&A performance evaluation.Then it puts forward the problems to be studied,and clarifies the significance,methods and contents of the research.Combining with the actual situation of Qingjin Biological M&A case,this paper mainly aims at the "five characteristics"(i.e.profitability,growth,security,liquidity and productivity)of the current business situation of enterprises,and constructs an evaluation system of accounting indicators.After screening and establishing the core financial index system,the weight of each index is determined by analytic hierarchy process,and the comprehensive benefits before and after M&A are calculated.The comprehensive benefits of enterprises before and after Qingjin Biological Merger and Acquisition are analyzed by radar chart.Select the core financial indicators data of industry benchmarking enterprises Guanhao Biology,and make a horizontal comparative analysis.Through comparative analysis,we can find out the direction that enterprises should pay attention to in future M&A,and provide practical financial analysis methods for enterprises to select M&A enterprises.In view of the future mergers and acquisitions of Qingda Biology,this paper puts forward the corresponding strategies to be improved and improved.According to the results of financial benefit analysis of Qingjin Biological M&A,enterprises should develop their strengths and avoid their weaknesses in the process of M&A.For the negative energy influencing factors,we should pay attention to improving in advance and steadily realize the strategic planning of enterprises.It is hoped that some useful research results can be obtained in similar M&A.